The end of the year is right around the corner. But this time of year actually is a beginning for certain healthcare stocks. That's because important share-performance catalysts and/or revenue opportunities lie just ahead. And that's why these players make great buys in November.
CRISPR Therapeutics (NASDAQ: CRSP) is submitting what may become its first commercialized gene-editing treatment to regulators this month. Axsome Therapeutics (NASDAQ: AXSM) just started selling a potential blockbuster antidepressant. And sales are multiplying for AbbVie 's (NYSE: ABBV) two key immunology drugs. These catalysts could lift the shares in the near term -- and over time. Let's take a closer look at each.
CRISPR is heading for a major moment. The gene-editing specialist, along with its partner Vertex Pharmaceuticals , begins a regulatory submission this month. The companies are requesting approval for exa-cel, an investigational therapy for blood disorders beta thalassemia and sickle cell disease.
For further details see:
3 Top Healthcare Stocks to Buy for November